Market's muted reaction to EPS fall may be due to expected business turnaround. However, with a 5% annual loss over five years, investors need to scrutinize data to ensure business soundness.

Vcanbio Cell & Gene Engineering's low ROE is offset by impressive earnings growth, potentially leading to long-term stock rise. The company's reinvestment of profits into the business is seen as a positive contributing factor.

Despite strong growth, the company's P/E ratio exceeding market average implies lofty investor expectations. However, current high P/E ratio poses risk to shareholders & potential investors with ongoing medium-term earnings trends.

Market growth expectations for Zhengyuan Zhihui Group seem moderated as average annual share price increase of 17% is lower than EPS growth of 27%. The high P/E ratio at 52.50 suggests continued market optimism despite potential short-term issues.